Archive · 13 Nov 2025
Biocon Anticipates 50% Drop in Biosimilar Development Costs Due to US Proposal
Imagine there are expensive medicines for serious sicknesses like cancer.
'Biosimilars' are like cheaper versions of these medicines that are made by different companies, like Biocon.
The United States has a new idea to make it easier and less costly for companies like Biocon to create these cheaper versions.
They want to change the rules so that companies don't have to do as many large tests to prove their cheaper medicine works.
Biocon's boss thinks this will cut their costs by half!
This means Biocon can make more of these cheaper medicines and bring them to people who need them faster and for less money.
Biocon is already selling some of these medicines in the US and plans to launch more soon, especially the ones for cancer.
Their sales from these medicines are growing fast, and they want to launch even more by the year 2030.
They are also looking into making cheaper versions of medicines that help people lose weight.
Biocon expects US proposal to halve biosimilar development costs, potentially by 50%.
The US FDA proposed simplifying clinical testing for biosimilars, reducing requirements for large efficacy trials.
This cost reduction is expected to allow Biocon to bring biosimilars to patients faster and at a more affordable price.
Biocon has seven biosimilars in the US market and plans to launch two more within six months.
The company's oncology biosimilar medicines hold a quarter of the US market share and will benefit from lower development costs.
- Who
- Biocon, led by CEO Shreehas Tambe of Biocon Biologics
- What
- Biocon anticipates a 50% reduction in biosimilar development costs due to a US FDA proposal to simplify clinical testing requirements, potentially leading to faster and more affordable access to these drugs.
- When
- Wednesday, November 13, 2025
- Where
- United States (proposal and market focus), Europe (market focus)
- Why
- The US FDA proposed to simplify drug testing for biosimilars, reducing the need for extensive clinical efficacy trials, which Biocon believes will significantly cut development costs.
Biocon's Perspective
US Regulatory Proposal
Impact of US Proposal on Development Costs
Biocon's Perspective
Biocon's CEO expects a 50% reduction in biosimilar development costs due to the US FDA's proposed changes, allowing for faster and more affordable market entry.
US Regulatory Proposal
The US FDA has proposed to simplify drug testing requirements for biosimilars, specifically by lowering the need for large comparative clinical efficacy trials.
Benefit for Existing Products
Biocon's Perspective
Biocon's oncology biosimilars, which hold a significant market share in the US, are expected to particularly benefit from these lower development costs.
US Regulatory Proposal
The proposal aims to streamline the testing process for biosimilars, making them more accessible to patients.
- Company
- Biocon
- Subsidiary Focus
- Biocon Biologics
- Proposed Cost Reduction
- 50%
- Biosimilar Revenue Growth
- 25% in latest quarter
- Biocon's Biosimilar Launch Goal
- 20 by 2030
- US Market Share (Oncology Biosimilars)
- One-fourth
- Upcoming Launches
- 2 in next six months
Sources
Biocon targets FY27 regulatory approvals for biosimilar to weight loss drug Ozempic
Biocon expects ₹300 crore annual savings from debt exits by FY27
Biocon banks on weight-loss drugs, raises stake in biosimilar arm
OneSource optimistic on weight-loss drug prospects, raises FY28 revenue guidance to over $500 mn
SBI Mutual Fund raises stake in Biocon to over 5%; shares surge 3%
Biocon shares up 10% in 2 days post Q2 show; Brokerages see further upside; check targets
Biocon share price jumps over 4% to hit 52-week high on reports of restructuring; Biologics IPO, merger under review
